Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI

Trial Profile

CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Candesartan cilexetil (Primary) ; Lisinopril
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms CALIBREX
  • Most Recent Events

    • 22 Jan 2019 Status changed from active, no longer recruiting to completed.
    • 09 Oct 2018 Planned End Date changed from 15 Nov 2018 to 15 Dec 2018.
    • 09 Oct 2018 Planned primary completion date changed from 15 Nov 2018 to 15 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top